Literature DB >> 1960307

Decreased coronary sinus oxygen content: a predictor of adverse prognosis in patients with severe congestive heart failure.

M White1, J L Rouleau, T D Ruddy, T De Marco, D Moher, K Chatterjee.   

Abstract

Patients with congestive heart failure have abnormal coronary hemodynamics, characterized by decreased coronary sinus oxygen content, increased coronary sinus blood flow and increased myocardial oxygen consumption. To evaluate their prognostic importance, the clinical characteristics and systemic and coronary hemodynamics were related to survival in 91 patients with severe congestive heart failure and decreased ejection fraction (25.5 +/- 10% [mean +/- SD]). In 69 patients congestive heart failure was due to or secondary to coronary artery disease (group 1) and in 22 it was due to idiopathic dilated cardiomyopathy (group 2). Five patients were in functional class II, 48 in class III and 38 in class IV. The median survival time was 20.7 months. As assessed with the Cox proportional hazards model, coronary sinus oxygen content was most strongly associated with a poor prognosis. On the basis of a comparison between the lowest (coronary sinus oxygen content less than or equal to 4.44 vol%) and highest quintile (coronary sinus oxygen content greater than 4.44 vol%), a low coronary sinus oxygen content was associated with a 2.34-fold increased risk of dying (95% confidence interval, 1.31 to 4.08). A low systolic blood pressure and a high diastolic pulmonary artery pressure were also significantly associated with increased mortality. Patients in the subgroup with a low coronary sinus oxygen content had values for functional class, ejection fraction and systemic hemodynamics similar to those of patients in the subgroup with high coronary sinus oxygen content. It is concluded that a low coronary sinus oxygen content indicative of noncompensated metabolic demand suggests a poor prognosis in patients with severe congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1960307     DOI: 10.1016/0735-1097(91)90495-u

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

Review 1.  Inhibitors of the renin-angiotensin system in established cardiac failure.

Authors:  K Chatterjee
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

2.  Prognostic significance of myocardial energy expenditure and myocardial efficiency in patients with heart failure with reduced ejection fraction.

Authors:  Mehmet S Cetin; Elif H Ozcan Cetin; Ugur Canpolat; Hatice Sasmaz; Ahmet Temizhan; Sinan Aydogdu
Journal:  Int J Cardiovasc Imaging       Date:  2017-08-14       Impact factor: 2.357

3.  Blood gas analysis of the coronary sinus in patients with heart failure.

Authors:  Jianghua Zhang; Chunfang Shan; Y U Zhang; Xianhui Zhou; Jinxin Li; Yaodong Li; Qiang Xing; Baopeng Tang
Journal:  Biomed Rep       Date:  2015-03-20

4.  Endogenous plasma endothelin concentrations and coronary circulation in patients with mild dilated cardiomyopathy.

Authors:  M Mundhenke; B Schwartzkopff; M Köstering; U Deska; R M Klein; B E Strauer
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

5.  Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy.

Authors:  Eric J Velazquez; Kerry L Lee; Robert H Jones; Hussein R Al-Khalidi; James A Hill; Julio A Panza; Robert E Michler; Robert O Bonow; Torsten Doenst; Mark C Petrie; Jae K Oh; Lilin She; Vanessa L Moore; Patrice Desvigne-Nickens; George Sopko; Jean L Rouleau
Journal:  N Engl J Med       Date:  2016-04-03       Impact factor: 91.245

6.  Angiographic Complete versus Clinical Selective Incomplete Percutaneous Revascularization in Heart Failure Patients with Multivessel Coronary Disease.

Authors:  Chieh-Yu Chang; Chun-Chi Chen; I-Chang Hsieh; Ming-Jer Hsieh; Cheng-Hung Lee; Dong-Yi Chen; Ming-Lung Tsai; Ming-Yun Ho; Jih-Kai Yeh; Yu-Chang Huang; Yu-Ying Lu; Chao-Yung Wang; Shang-Hung Chang; Ming-Shien Wen
Journal:  J Interv Cardiol       Date:  2020-07-27       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.